Palliative Care in Children with Inherited Metabolic Diseases: Why does it matter?
Joana Pereira MendesAndreia NogueiraEma GriloSara FerreiraLuísa DiogoCândida CancelinhaPublished in: Endocrine, metabolic & immune disorders drug targets (2023)
Our cohort includes a group of children with severe, complex and neurodegenerative IMD. They need multiple medications for symptoms control, are highly dependent on medical devices and consume significant healthcare resources. Communication impairment adds complexity being a major barrier to symptom assessment. PPCT referral allowed home support, anticipated care plans development with end of life and bereavement support, as well as a tendency towards a reduction in EDA. These findings reinforce the need for holistic approach to identify and address the PPC needs of children with IMD.